IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Banki Haddock Fiora v Glaxo Group Limited [2024] APO 20
Patent:2018282427
Title:COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST
Patentee:Glaxo Group Limited
Opponent:Banki Haddock Fiora
Delegate:Dr S. J. Smith
Decision Date: 28 May 2024
Hearing Date: 28 February 2024, by videoconference
Catchwords: PATENTS – section 75 – opposition to grant of an extension of term – section 71 – approved form for application for an extension of term – pharmaceutical substance per se an admixture – relevant earliest first regulatory approval date – nature of goods included on the ARTG – opposition unsuccessful – costs awarded
Representation: Counsel for the patentee: David Shavin KC
Patent attorney for the patentee: Annabella Newton of Phillips Ormonde Fitzpatrick
Counsel for the opponent: David Larish
Solicitor for the opponent: Banki Haddock Fiora
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent:2018282427
Title:COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST
Patentee:Glaxo Group Limited
Date of Decision: 28 May 2024
DECISION
The opposition to grant of an extension of term of patent 2018282427 is unsuccessful. Subject to appeal, I grant the extension of term.
I award costs according to Schedule 8 against Banki Haddock Fiora.
REASONS FOR DECISION
Background
This matter concerns an opposition to an extension of term of patent number 2018282427 (the patent) in the name of Glaxo Group Limited (the patentee). The patent was granted on 15 July 2021 and the patentee filed an application for an extension of term (the application) of the patent under section 70 of the Patents Act 1990 (the Act) on 3 November 2021.
The application is based on the product TRELEGY ELLIPTA, which was first listed on the Australian Register of Therapeutic Goods (ARTG) on 16 January 2018. Prior to consideration of the application, the patent was re-examined pursuant to section 97 of the Act and the patentee made section 104 amendments to the claims and description which were allowed unopposed on 16 June 2022. The application was advertised accepted on 7 July 2022.
Banki Haddock Fiora (the opponent) filed a notice of opposition on 7 October 2022 and a statement of grounds and particulars on 23 December 2022. The statement of grounds and particulars identifies the ground as follows: “The Application incorrectly treated the earliest first regulatory approval date as the inclusion of Trelegy Ellipta on the ARTG when the actual earliest first regulatory approval date was the inclusion of Anoro Ellipta on the ARTG.” At the hearing I confirmed with the opponent that this reflected an opposition on the basis that the requirements of section 71 were not satisfied.[1]
[1] I note that the opponent also observed that the combined effect of sections 76 and 77 is that an extension of zero term could be granted following the opposition.
On 3 January 2023 a delegate of the Commissioner directed that the documents that accompanied the statement of grounds and particulars (various documents concerning the TRELEGY ELLIPTA and ANORO ELLIPTA products and the…
Keep reading for free
Create a free CaseChat account to read Banki Haddock Fiora v Glaxo Group Limited and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2024] APO 20
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi